Anti-vegf Injections for Macular Degeneration — Explained by Medical Evidence, Not Myths

Anti-VEGF injections for macular degeneration are a standard, evidence-based treatment for wet age-related macular degeneration. They work by blocking a growth signal that causes abnormal blood vessels to leak under the retina, helping preserve vision and, in many people, improve it.

Overview: what anti-VEGF injections do

Anti-VEGF injections for macular degeneration are medications placed inside the eye to treat wet age-related macular degeneration, often called wet AMD. They block vascular endothelial growth factor, or VEGF, a protein that promotes the growth of fragile, abnormal blood vessels under the macula. When those vessels leak fluid or blood, central vision can become blurred, distorted, or quickly reduced.

This treatment is supported by strong medical evidence and is considered a mainstay of care for wet AMD. In many patients, it slows vision loss significantly, and some people notice improvement in reading vision, detail, or distortion after treatment begins. The goal is usually to preserve useful central vision for as long as possible.

It is important to understand that anti-VEGF injections do not usually cure macular degeneration or reverse all existing damage. Instead, they help control disease activity over time. Because wet AMD can reactivate, treatment often requires follow-up scans, repeat injections, and an individualized plan guided by an eye specialist.

Macular degeneration and who may benefit

The macula is the central part of the retina responsible for sharp, detailed vision needed for reading, driving, and recognizing faces. Age-related macular degeneration affects this area and is broadly divided into dry AMD and wet AMD. Dry AMD is more common and progresses more slowly, while wet AMD is less common but more likely to cause faster and more severe central vision loss.

Anti-VEGF injections are used for wet AMD because this form involves abnormal new blood vessels, also called choroidal neovascularization. These vessels can leak fluid, lipids, or blood, damaging the macula. A person may notice straight lines looking wavy, a dark or empty spot in the center of vision, difficulty reading, or reduced clarity in one eye.

Not every person with AMD needs injections. People with dry AMD are usually managed differently, with monitoring, lifestyle measures, and in some cases nutritional guidance. Patients who develop the wet form may be evaluated for urgent treatment by a retina specialist, often alongside testing for macular degeneration.

What the evidence shows, and common myths

Medical evidence from large clinical studies shows that anti-VEGF therapy can stabilize vision in many patients with wet AMD and improve vision in a meaningful portion of them. This marked a major change in care compared with older approaches that were less effective at preventing central vision decline. Outcomes tend to be better when treatment starts early, before extensive scarring or permanent retinal damage has developed.

Several myths can cause unnecessary worry. One myth is that injections are only used when vision is already beyond saving. In fact, the opposite is true: timely treatment is most valuable when started promptly after wet AMD is diagnosed. Another myth is that one injection fixes the problem permanently. Wet AMD usually behaves like a chronic condition, so treatment commonly continues at intervals based on response.

A further myth is that the injection itself is usually very painful. In practice, the eye is numbed first, the procedure is brief, and most people describe pressure or mild discomfort rather than severe pain. Some irritation, tearing, or a scratchy feeling later that day can happen, but persistent or worsening pain should be assessed by a doctor.

There is also a misconception that anti-VEGF injections treat all forms of central vision loss. They are specifically targeted to diseases driven by abnormal retinal vessel leakage. A retina specialist determines whether symptoms are due to wet AMD or another eye problem requiring a different plan.

How the diagnosis is confirmed before treatment

Before recommending injections, the ophthalmologist confirms that wet AMD is present and assesses how active it is. This usually starts with a detailed eye examination after the pupils are dilated. The doctor may ask about blurred central vision, distortion, missing areas, changes in color perception, and how quickly symptoms appeared.

Optical coherence tomography, often called OCT, is one of the most important tests. It creates cross-sectional images of the retina and can show fluid, thickening, or structural changes in the macula. Retinal photography and fluorescein angiography may also be used in some patients to show leaking abnormal vessels and help guide treatment decisions.

Because wet AMD can resemble or coexist with other retinal conditions, diagnosis should be precise. People may also undergo a general review of risk factors such as age, smoking history, family history, cardiovascular health, and whether the other eye has signs of AMD. If needed, a specialist may discuss eye examination findings and whether further retinal imaging is helpful.

What happens during anti-VEGF treatment

Anti-VEGF injections are usually given in an outpatient clinic by a retina specialist or ophthalmologist. The eye is cleaned carefully to reduce infection risk, and anesthetic drops or gel are used to numb the surface. A small device may be used to keep the eyelids open. The injection itself takes only a few seconds.

Afterward, the patient may notice mild redness on the white of the eye, temporary blurring, watering, a gritty sensation, or small floating spots or bubbles that fade. Most people return home the same day. Driving immediately afterward may not be ideal if vision is blurred, so some patients arrange transportation.

Several anti-VEGF medicines may be used, and the exact choice depends on clinical judgment, retinal findings, treatment response, and local practice. The schedule often begins with a series of injections and then continues based on monitoring. Some people are treated monthly for a period, while others move to a treat-and-extend or as-needed approach once the retina becomes more stable.

Follow-up is an essential part of treatment. OCT scans and vision checks help determine whether fluid has resolved, whether another injection is needed, and how the disease is behaving over time. In centers offering advanced eye care procedures, treatment planning is usually coordinated between comprehensive ophthalmology and retina teams.

Benefits, limits, and possible risks

The main benefit of anti-VEGF therapy is protection of central vision. Many patients experience stabilization, and some gain lines of vision on formal testing. Treatment may reduce retinal swelling, bleeding, and distortion, which can improve daily activities such as reading larger print, recognizing faces, or navigating familiar environments.

However, there are limits. Vision may not return to normal, especially if scarring, atrophy, or long-standing damage is already present. Treatment also does not remove the underlying age-related tendency toward macular degeneration. This is why regular follow-up remains important even when the eye seems stable.

Serious complications are uncommon but possible with any injection into the eye. These include infection inside the eye, significant bleeding, retinal tear or detachment, and a rise in eye pressure. Mild temporary discomfort or redness is more common and usually settles. Patients should be given clear instructions about warning symptoms after the procedure.

Some patients worry about whether repeated injections are safe. Specialists weigh the benefits and risks carefully at every visit. If the disease remains active, the risk of untreated wet AMD to central vision is often much greater than the risk from properly performed injections.

Self-care, monitoring, and living with AMD

Self-care does not replace medical treatment for wet AMD, but it can support eye health and help patients respond promptly to changes. Using an Amsler grid at home may help detect new distortion or blank spots in central vision. Any sudden change, especially in one eye, should be reported quickly rather than waiting for the next routine appointment.

General health habits matter. Not smoking is one of the most important steps, as smoking is a major risk factor for AMD progression. A balanced diet rich in vegetables and fish, attention to blood pressure and cardiovascular health, and routine eye checkups may also be advised. Some people with certain forms of dry AMD may be told about specific eye vitamin formulations, but these do not treat wet AMD directly.

Low vision support can also make a meaningful difference. Brighter lighting, magnifiers, large-print devices, electronic reading aids, and practical home adjustments may help maintain independence. If both eyes are affected or daily tasks become more difficult, referral to low vision services can be useful.

For international patients seeking assessment, Acibadem International’s multidisciplinary specialists in JCI-accredited hospitals diagnose and treat retinal conditions, including retina diseases, with individualized ophthalmology care plans.

When to seek medical care

Anyone who notices new central blurring, straight lines appearing wavy, a dark spot in the center of vision, or a sudden drop in sight should arrange prompt evaluation by an eye doctor. Wet AMD can progress quickly, and early treatment often offers the best chance of preserving vision.

After an injection, urgent medical attention is needed if there is severe or worsening eye pain, rapidly increasing redness, marked sensitivity to light, pus-like discharge, or a sudden major decrease in vision. These symptoms may suggest a complication that should be assessed without delay.

Regular scheduled follow-up is also important even when symptoms seem stable. Wet AMD activity can return before it becomes obvious in everyday vision, and monitoring helps the specialist adjust treatment at the right time. A doctor can also determine whether symptoms might be related to another condition, such as glaucoma, cataract, or a different retinal disorder.

Frequently asked questions

Do anti-VEGF injections cure macular degeneration?

They do not usually cure age-related macular degeneration. For wet AMD, they help control abnormal blood vessel leakage and can slow vision loss, often preserving sight and sometimes improving it. Ongoing monitoring is usually needed because the condition can become active again.

Are anti-VEGF injections used for dry macular degeneration?

These injections are mainly used for wet AMD, not the common dry form. Dry AMD has different changes in the retina and is usually managed with monitoring, lifestyle advice, and, in some cases, nutritional guidance. An eye specialist can explain which type is present.

How often are injections needed?

The schedule varies from person to person. Many patients start with more frequent injections and then continue at intervals based on retinal scans and visual response. Some need ongoing regular treatment, while others can go longer between visits once the eye is stable.

Are the injections painful?

The eye is numbed before the injection, so the procedure is usually well tolerated. Many people feel pressure or brief discomfort rather than strong pain. Mild irritation or a scratchy feeling afterward can occur for a short time.

Can vision improve after treatment starts?

Yes, some patients experience clearer central vision or less distortion after treatment. However, the main aim is often to stop further damage and preserve useful vision. The amount of improvement depends on how active the disease is and whether permanent retinal damage has already occurred.

What symptoms after an injection need urgent review?

Severe pain, worsening redness, marked light sensitivity, sudden vision loss, or discharge should be assessed urgently. These symptoms are not typical of routine post-procedure irritation and may signal a complication. Patients should follow the instructions provided by their ophthalmology team.

References

• American Academy of Ophthalmology
• National Eye Institute
• National Health Service
• Royal College of Ophthalmologists
• Cochrane

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.